Non-steroidal anti-inflammatory drugs

  • Andrew Whelton
  • Til Sturmer
  • George A. Porter

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennet WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28(Suppl 1): 56–62.Google Scholar
  2. 2.
    Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insights. J Nephrol 1998; 11: 70–75.PubMedGoogle Scholar
  3. 3.
    Whelton A. Nonsteroidal anti-inflammatory drugs: effects on kidney function. In: Primer On Kidney Diseases. Greenberg A (editor). Academic Press, San Diego 1994; 163–167.Google Scholar
  4. 4.
    Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiological foundations and clinical implications. Am J Med 1999; 106: 13S–24S.CrossRefPubMedGoogle Scholar
  5. 5.
    Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999; 107: 65S–71S.CrossRefPubMedGoogle Scholar
  6. 6.
    Personal communication, Evans T, McNeil Consumer Health Care, 2000.Google Scholar
  7. 7.
    Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588–598.PubMedGoogle Scholar
  8. 8.
    Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1–12.PubMedGoogle Scholar
  9. 9.
    Breyer MD, Harris RC. Cyclooxgenase-2 and the kidney. Curr Opin Nephrol Hypertens 2001; 10: 89–98.PubMedGoogle Scholar
  10. 10.
    Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ II. Clinical implications of prostaglandin and thromboxane A2 formation (2 parts). N Engl J Med 1988; 319: 689–69 and 761–767.PubMedGoogle Scholar
  11. 11.
    FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 6: 433–442.Google Scholar
  12. 12.
    Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563–572.PubMedGoogle Scholar
  13. 13.
    Stokes JB. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle: selective inhibition of the medullary portion. J Clin Invest 1979; 64: 495–502.PubMedGoogle Scholar
  14. 14.
    Breyer MD, Zhang YH, Guan YF, Hao CM, Herbert RL, Breyer RM. Regulation of renal function by prostaglandin E receptors. Kidney Int 1998; 54: S88–S94.CrossRefGoogle Scholar
  15. 15.
    O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci 1992; 89: 4888–4892.PubMedGoogle Scholar
  16. 16.
    Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24(Suppl 49): 15–19.Google Scholar
  17. 17.
    Hla T, Nielson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci 1992; 89: 7384–7386.PubMedGoogle Scholar
  18. 18.
    Kömhoff M, Gröne HJ, Klein T, Seyberth HW, Nusing R. Localization of cyclooxygenase-1 and-2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272(4 Pt 2): F460–468.PubMedGoogle Scholar
  19. 19.
    Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase 2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–2510.PubMedGoogle Scholar
  20. 20.
    Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001; 110(3 Suppl 1): 33–42.Google Scholar
  21. 21.
    Blume C, Heise G, Muhlfeld A, Bach D, Schrork K, Gerhardz CD, Grabensee B, Heering P. Effect of flosulide, a selective cyclooxygenase inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56: 1770–1778.CrossRefPubMedGoogle Scholar
  22. 22.
    Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis S. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465–1470.CrossRefPubMedGoogle Scholar
  23. 23.
    Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1994; 90: 11693–11697.Google Scholar
  24. 23a.
    McMurray RW, Hardy KJ: COX-2 inhibitors: Today and tomorrow. Am J Med Sci. 2002; 323: 181–189.PubMedGoogle Scholar
  25. 24.
    Harris RC. Cyclooxygenase — 2 in the kidney. J Am Soc Nephrol 2000; 11: 2387–2394.PubMedGoogle Scholar
  26. 25.
    Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1–12.PubMedGoogle Scholar
  27. 26.
    Stokes JB, Kokko JP. Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. J Clin Invest 1977; 59: 1099–1104.PubMedGoogle Scholar
  28. 27.
    Whelton A, Hamilton CW: Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588–598.PubMedGoogle Scholar
  29. 28.
    Schlondorf D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643–653.Google Scholar
  30. 29.
    Murray MD, Brater DC, Tierney WM, Hui SL, McDonald CJ. Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci 1990; 229: 222–229.Google Scholar
  31. 30.
    Whelton A. Renal and related cardiovascular effects of conventional and COX-2 specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7: 63–74.PubMedGoogle Scholar
  32. 31.
    Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–741.PubMedGoogle Scholar
  33. 32.
    Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109–1120.PubMedGoogle Scholar
  34. 32a.
    Ormrod D, Wellington K, Wagstaff AJ: Valdecoxib. Drugs 2002; 62: 2059–2071.CrossRefPubMedGoogle Scholar
  35. 33.
    Sedor JR, Williams SL, Chremos AN, Johnson CL, Dunn MJ. Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clin Pharmacol Ther 1984; 36: 85–91.PubMedGoogle Scholar
  36. 34.
    Berg KJ. Acute effects of acetylsalicylic acid on renal function in normal man. Eur J Clin Pharmacol 1977; 11: 117–123.PubMedGoogle Scholar
  37. 35.
    Donker AJ, Arisz L, Brentjens JR, van der Hem GK, Hollemans HJ. The effect of indomethacin on kidney function and plasma renin activity in man. Nephron 1976; 17: 288–296.PubMedGoogle Scholar
  38. 36.
    Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156: 2433–2439.CrossRefPubMedGoogle Scholar
  39. 37.
    Evans JMM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, McDevitt DG, MacDonald TM. Non-steroidal drugs anti-inflammatory drugs and hospitalization for acute renal failure. QJMed 1995; 88: 551–557.Google Scholar
  40. 38.
    Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488–496.PubMedGoogle Scholar
  41. 39.
    Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of nonsteroidal anti-inflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 1985; 14: 163–175.CrossRefPubMedGoogle Scholar
  42. 40.
    Feldman HI, Kinman JL, Berlin JA, Hennessy S, Kimmel SE, Farrar J, Carson JL, Strom BL. Parenteral ketorolac: the risk of acute renal failure. Ann Intern Med 1997; 126: 193–199.PubMedGoogle Scholar
  43. 41.
    Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48: 895–900.PubMedGoogle Scholar
  44. 42.
    Zipser RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983; 84: 697–703.PubMedGoogle Scholar
  45. 43.
    Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible mechanisms. Ann Intern Med 1979; 91: 47–49.PubMedGoogle Scholar
  46. 44.
    Arisz L, Donker AJM, Brentjens JRH, van der Hem GK. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976; 199: 121–125.PubMedGoogle Scholar
  47. 45.
    Kleinknecht C, Broyer M, Gubler MC, Palcoux JB. Irreversible renal failure after indomethacin in steroid-resistant nephrosis. N Engl J Med 1980; 302: 691.PubMedGoogle Scholar
  48. 46.
    Kimberley RP, Gill JR Jr, Bowden RE, Keiser HR, Plotz PH. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 1978; 89: 336–341.Google Scholar
  49. 47.
    Fong HJ, Cohen AH. Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982; 2: 28–31.PubMedGoogle Scholar
  50. 48.
    Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982; 96: 317–20.PubMedGoogle Scholar
  51. 49.
    Whelton A, Stout RL, Spilman PS, Klassen DL. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med 1990; 112: 568–576.PubMedGoogle Scholar
  52. 50.
    Whelton A. Renal effects of over-the-counter analgesics. J Clin Pharmacol 1995; 35: 454–463.PubMedGoogle Scholar
  53. 51.
    Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109: 307–314.CrossRefPubMedGoogle Scholar
  54. 52.
    Galler M, Folkert VW, Schlondorff D. Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA 1981; 246: 154–155.CrossRefPubMedGoogle Scholar
  55. 53.
    Findling JW, Beckstrom D, Rawsthorne L, Kozin F, Itskovitz H. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA 1980; 244: 1127–1128.CrossRefPubMedGoogle Scholar
  56. 54.
    Nicholls MG, Espiner EA. Indomethacin-induced azotaemia and hyperkalemia: a case study. N Z Med J 1981; 94: 377–379.PubMedGoogle Scholar
  57. 55.
    Paladini G, Tonazzi C. Indomethacin-induced hyperkalemia and renal failure in multiple myeloma. Acta Haematol 1982; 68: 256–260.PubMedGoogle Scholar
  58. 56.
    Akbarpour F, Afrasiabi A, Vaziri ND. Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J 1985; 78: 756–757.PubMedGoogle Scholar
  59. 57.
    Mor R, Pitlik S, Rosenfeld JB. Indomethacin-and moduretic-induced hyperkalemia. Isr J Med Sci 1983; 19: 535–537.PubMedGoogle Scholar
  60. 58.
    Goldszer RC, Coodley EL, Rosner MJ, Simons WM, Schwartz AB. Hyperkalemia associated with indomethacin. Arch Intern Med 1981; 141: 802–804.CrossRefPubMedGoogle Scholar
  61. 59.
    MacCarthy EP, Frost GW, Strokes GS. Indomethacin-induced hyperkalemia. Med J Aust 1979; 1: 550.PubMedGoogle Scholar
  62. 60.
    Tan SY, Shapiro R, Franco R, Stockard H, Mulrow PJ. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med 1979; 90: 783–785.PubMedGoogle Scholar
  63. 61.
    Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159–175.PubMedGoogle Scholar
  64. 62.
    Palmer RH, Haig AE, Flavin SK, Iyengar NK. Effects of ibuprofen, nabumetone and celecoxib on blood pressure control in hypertensive patients on ACE inhibitors. Am J Hypertens 2001; 14: 85A.CrossRefGoogle Scholar
  65. 63.
    White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hyperten 2002;39:929–934.Google Scholar
  66. 64.
    Vioxxâ [package insert]. Whitehouse Station, NJ: Merck & Co, March 2000.Google Scholar
  67. 65.
    Orloff J, Handler JS, Bergstrom S. Effect of prostaglandin (PGE1) on the permeability response of the toad bladder to vasopressin, theophylline and adenosine 3′, 5′-monophosphate. Nature 1965; 205: 397–398.PubMedGoogle Scholar
  68. 66.
    Anderson RJ, Berl T, McDonald KM, Schrier RW. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest 1975; 56: 420–426.PubMedGoogle Scholar
  69. 67.
    Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977; 237: 1716–1717.CrossRefPubMedGoogle Scholar
  70. 68.
    Blum M, Aviram A. Ibuprofen induced hyponatremia. Rheumatol Rehabil 1980; 19: 258–259.PubMedGoogle Scholar
  71. 69.
    Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of anti-hypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272: 781–786.PubMedGoogle Scholar
  72. 70.
    Pope JE, Anderson JJ, Felson, DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477–484.CrossRefPubMedGoogle Scholar
  73. 71.
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis [see comments]. Ann Intern Med 1994; 121: 289–300.PubMedGoogle Scholar
  74. 71a.
    Fogari R, Zoppi A, Carretta R Veglio F, Salvetti A: Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicenter study. J Hyperten 2002;20:1007–1014.Google Scholar
  75. 72.
    Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998; 20: 376–387.CrossRefPubMedGoogle Scholar
  76. 73.
    Schwartz JI, Malice MP, Kalyani R, Lasseter K, Holmes GB, Gertz BJ, Gottesdiener K, Laurenzi M, Brune K. Effect of rofecoxib, celecoxib, and naproxen on blood pressure in elderly volunteers. Am J Hypert 2001; 14: 177A.Google Scholar
  77. 73a.
    Celis H, Thijs L, Staessen JA, Birkenhager WH, Bulpitt CJ, deLeeuw PW, Leonetti G, Nachev C, Tuomilehto J, Fagard RH: Interaction between nonsteroidal anti-inflammatory drug intake and calcium channel blocker-based antihypertensive treatment in Syst-Eur trial. J Human Hyperten 2001;15:613–8.Google Scholar
  78. 74.
    Raij L, Baylis C. Nitric oxide and the glomerulus. Kidney Int 1995; 48: 20–32.PubMedGoogle Scholar
  79. 75.
    Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Basile Fasolo C, Sudano I, Salvetti A. Aging and endothelial function in the normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981–1987.PubMedGoogle Scholar
  80. 76.
    Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349: 837–842.CrossRefPubMedGoogle Scholar
  81. 77.
    Campese VM, Amar M, Anjali C, Medhat T, Wurgaft A: Effect of L-arginine on systemic and renal haemondynamics in salt-sensitive patients with essential hypertension. J Hum Hyperten. 1997; 11: 527–532.Google Scholar
  82. 78.
    Perinotto P, Biggi A, Carra N, Orrico A, Valmadre G, Dalľaglio P, Novarinin A, Montanari A. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. J Am Soc Nephrol 2001; 12: 1706–1712.PubMedGoogle Scholar
  83. 79.
    Mulkerrin EC, Clark BA, Epstein FH: Increased salt retention and hypertension from non-steroidal agents in the elderly. Q J Med 1997; 90: 411–415.Google Scholar
  84. 80.
    Alam S, Purdie DM, Johnson AG. Evaluation of the potential interaction between NaCl and prostaglandin inhibition in elderly individuals with isolated systolic hypertension J Hyperten 1999; 17: 1195–1202.Google Scholar
  85. 81.
    Brater DC, Anderson S, Baird B, Campbell WB. Effects of ibuprofen, naproxen, and sulindac on prostaglandings in men. Kidney Int 1985; 27: 66–73.PubMedGoogle Scholar
  86. 82.
    Bunning RD, Barth WF. Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA 1982; 248: 2864–2867.CrossRefPubMedGoogle Scholar
  87. 83.
    Ciabattoni G, Cinotti GA, Pierucci A, Simonetti BM, Manzi M, Pugliese F, Barsotti P, Pecci G, Taggi F, Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease: evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984; 310: 279–283.PubMedGoogle Scholar
  88. 84.
    Klassen DK, Stout RL, Spilman PS, Whelton AW. Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. J Clin Pharmacol 1989; 29: 1037–1042.PubMedGoogle Scholar
  89. 85.
    Mistry CD, Lote CJ, Gokal R, Currie WJ, Vandenberg M, Mallick NP. Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency. Clin Sci 1986; 70: 501–505.PubMedGoogle Scholar
  90. 86.
    Quintero E, Gines P, Arroya V, Rimola A, Camps J, Gaya J, Guevara A, Rodamilans M, Rodes J. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in patients with cirrhosis and ascites. Nephron 1986; 42: 298–303.PubMedGoogle Scholar
  91. 87.
    Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60: 804–817.CrossRefPubMedGoogle Scholar
  92. 88.
    Porile JL, Bakris GL, Garella S. Acute interstitial nephritis with glomerulonephropathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol 1990; 30: 468–475.PubMedGoogle Scholar
  93. 88a.
    Rocha JL, Fernandez-Alonso J: Acute interstitial nephritis associated with the seledcitve COX-2 enzyme inhibitor, rofecoxib. Lancet 2001;357:1946–1947.CrossRefPubMedGoogle Scholar
  94. 88b.
    Henao, J, Hisamuddin J, Nzerue CM, Vasandaui G, Hewan-Lowe K: Celecoxib-induced acute interstitial nephritis. Am J Kid Dis 2002:39:1313–1317.PubMedGoogle Scholar
  95. 88c.
    Alper AB, Meleg-Smith S, Krane NK: Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kid Dis 2002;40:1086–1090.PubMedGoogle Scholar
  96. 89.
    Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4: 1–6.PubMedGoogle Scholar
  97. 90.
    Levin ML. Patterns of tubulo-interstitial damage associated with nonsteroidal anti-inflammatory drugs. Sem Nephrol 1988; 8: 55–61.Google Scholar
  98. 91.
    Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54: 179–190.PubMedGoogle Scholar
  99. 92.
    Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal anti-inflammatory drugs. Evidence for a common mechanism. Br J Clin Pharmacol 1999; 47: 203–210.CrossRefPubMedGoogle Scholar
  100. 93.
    Bender WL, Whelton A, Beschorner WE, Darwish MO, Hall-Craggs M, Solez K. Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs: immunologic characterization of the inflammatory infiltrate. Am J Med 1984; 76: 1006–1012.CrossRefPubMedGoogle Scholar
  101. 94.
    Stachura I, Jayakumar S, Bourke E. T+B lymphocyte subsets in fenoprofen nephropathy. Am J Med 1983; 75: 9–16.CrossRefPubMedGoogle Scholar
  102. 95.
    Shibasaki T, Ishimoto F, Sakai O, Joh K, Aizawa S. Clinical characterization of drug-induced allergic nephritis. Am J Nephrol 1991;11:174–180.PubMedGoogle Scholar
  103. 96.
    Radford MGJr, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, McCarthy JT: reversible membranous nephropathy associated with the used of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276: 466–469.CrossRefPubMedGoogle Scholar
  104. 97.
    Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the used of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med 1994; 331: 1675–1679.CrossRefPubMedGoogle Scholar
  105. 98.
    Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk of chronic renal disease. Ann Intern Med 1991; 115: 165–172.PubMedGoogle Scholar
  106. 99.
    Field TS, Gurwitz JH, Glynn RJ, Salive ME, Gaziano JM, Taylor JO, Hennekens CH. The renal effects of nonsteroidal anit-inflammatory drugs in older people: findings from the established populations for epidemiologic studies of the elderly. J Am Soc Geriatr Soc 1999; 47: 507–511.Google Scholar
  107. 100.
    Sturmer T, Elseviers MM, De Broe ME. Nonsteroidal anti-inflammatory drugs and the kidney. Curr Opin Nephrol Hypert 2001; 10: 161–163.Google Scholar
  108. 101.
    Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of non-steroidal antiinflammatory drugs: The importance of half-life and other medications. Am J Med 2001; 111: 521–527.PubMedGoogle Scholar
  109. 102.
    Calvo-Alen J, De Cos MA, Rodriguez-Valverde V, Escallada R, Florez J, Arias M. Subclinical renal toxicity in rheumatic patients receiving longterm treatment with nonsteroidal anti-inflammatory drugs. J Rheum 1994; 21: 1742–1747.PubMedGoogle Scholar
  110. 103.
    Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominate analgesic. Am J Kidney Dis 1996; 24: 17–24.Google Scholar
  111. 104.
    Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981; 24: 1208–1210.PubMedGoogle Scholar
  112. 105.
    Robertson CE, Ford MJ, Van Somerem V, Dlugolecka M, Prescott LF. Mefenamic acid nephropathy. Lancet 1980; 2: 232–233.PubMedGoogle Scholar
  113. 106.
    Husserl FE, Lange RK, Kantorw CMJ. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979; 242: 1896–1898.CrossRefPubMedGoogle Scholar
  114. 107.
    Atta MG, Whelton A. Acute renal papillary necrosis induced by ibuprofen. Am J Ther 1996; 4: 55–60Google Scholar
  115. 108.
    Kincaid-Smith P. Effects of non-narcotic analgesics on the kidney. Drugs 1986; 32(Suppl 4): 109–128.PubMedGoogle Scholar
  116. 109.
    Kirschenbaum MA, White N, Stein JH, Ferris TF. Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. Am J Med 1974; 227: 801–805.Google Scholar
  117. 110.
    Stein JH, Fadem SZ. The renal circulation. JAMA 1978; 239: 1308–1312.CrossRefPubMedGoogle Scholar
  118. 111.
    Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981; 24: 1208–1210.PubMedGoogle Scholar
  119. 112.
    Lourie SH, Denman SJ, Schroeder ET. Association of renal papillary necrosis and ankylosing spondylitis. Arthritis Rheum 1977; 20: 917–921.PubMedGoogle Scholar
  120. 113.
    Morales A, Steyn J. Papillary necrosis following phenylbutazone ingestion. Arch Surg 1971; 103: 420–421.PubMedGoogle Scholar
  121. 114.
    Husserl FE, Lange RK, Kantrow CM Jr. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979; 242: 1896–1898.CrossRefPubMedGoogle Scholar
  122. 115.
    Robertson CE, Ford MJ, Van Someren V, Dlugolecka M, Prescott LF. Mefenamic acid nephropathy. Lancet 1980; 2: 232–233.PubMedGoogle Scholar
  123. 116.
    Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyren O. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801–1808.CrossRefPubMedGoogle Scholar
  124. 117.
    Weisman JI, Bloom B. Anuria following phenylbutazone therapy. N Engl J Med 1955; 252: 1086–1087.PubMedGoogle Scholar
  125. 118.
    Lipsett MB, Goldman R. Phenylbutazone toxicity: report of a case of acute renal failure. Ann Intern Med 1954; 41: 1075–1079.PubMedGoogle Scholar
  126. 119.
    Hart D, Ward M, Lifschitz MD. Suprofen-related nephrotoxicity. A distinct clinical syndrome. Ann Intern Med 1987; 106: 235–238.PubMedGoogle Scholar
  127. 120.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–235.PubMedGoogle Scholar
  128. 121.
    Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. COX-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8: 49–64.PubMedGoogle Scholar
  129. 122.
    Lipsky PE, Abramson SB, Crofford L, Dubois MD, Simon LS, van de Putte LBA: the classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25: 2298–2303.PubMedGoogle Scholar
  130. 123.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–1255.CrossRefPubMedGoogle Scholar
  131. 124.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, for the VIGOR study group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–1528.CrossRefPubMedGoogle Scholar
  132. 125.
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–1690.PubMedGoogle Scholar
  133. 126.
    Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a new cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized controlled trial. J Clin Pharmacol 2000; 40: 124–132.CrossRefPubMedGoogle Scholar
  134. 127.
    Cryer B, Gottesdiener K, Gertz B, Wong P, Dallob A, Feldman M. In vivo effects of rofecoxib, a new cyclooxygenase (COX)-inhibitor, on gastric mucosal prostaglandin (PG) and serum thromboxane (TXB2) synthesis in healthy humans. Gastroenterology 1999; 116: G0611.Google Scholar
  135. 128.
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929–1933.CrossRefPubMedGoogle Scholar
  136. 129.
    O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–160.PubMedGoogle Scholar
  137. 130.
    Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76–84.PubMedGoogle Scholar
  138. 131.
    Swan, SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson P, Schwartz JK, Musliner TA, Gertz BJ, Brater C, Yao SL. Effects of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133: 1–9.PubMedGoogle Scholar
  139. 132.
    Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85–95.PubMedGoogle Scholar
  140. 133.
    Whelton A, White WB Bello AE, Puma JA, Fort JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients >or= 65years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959–963.CrossRefPubMedGoogle Scholar
  141. 133a.
    Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC: Nonnarcotic analgesic use and the risk of hypertension in US women. Hyperten 2002; 40: 604–608.Google Scholar
  142. 134.
    Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood-pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–838.PubMedGoogle Scholar
  143. 134a.
    Kilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U: Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 2002;42:985–994.Google Scholar
  144. 134b.
    Reitblat T, Zamir D, Estis L, Priluk R, Drogenikov T, Viskoper JR: The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Human Hyperten. 2002;16:431–434.Google Scholar
  145. 135.
    American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2000.Google Scholar
  146. 136.
    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.Google Scholar
  147. 137.
    Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CS, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-Eur) Trial Investigators. Lancet 1997; 350: 757–764.PubMedGoogle Scholar
  148. 138.
    ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–1975.Google Scholar
  149. 139.
    Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.CrossRefPubMedGoogle Scholar
  150. 140.
    Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90(Suppl 5A): 42–47.Google Scholar
  151. 141.
    Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35: 937–940.PubMedGoogle Scholar
  152. 142.
    Wolf G, Porth H, Stahl RAK. Acute renal failure associated with rofecoxib. Ann Intern Med 2000; 133: 394 [letter].PubMedGoogle Scholar
  153. 142a.
    Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Safety 2002;25:537–544.CrossRefPubMedGoogle Scholar
  154. 142b.
    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM: A comparison of renal-related adverse drug rfeactions between rofecoxib and celecoxib, based on World Health Organization/Uppsala Monitoring Centre safety database. Clin Therap 2001;23:1478–1491.Google Scholar
  155. 143.
    Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108–1112.CrossRefPubMedGoogle Scholar
  156. 144.
    Page K, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An unrecognized public health problem. Arch Intern Med 2000; 160: 777–784.CrossRefPubMedGoogle Scholar
  157. 144a.
    Feenstra J, Heerdink ER, Grobbee DE, Stricker BHC: Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam study. Arch Intern Med 2002;162: 265–270.CrossRefPubMedGoogle Scholar
  158. 145.
    Graham DY, Agrawal MN, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebocontrolled trial. Lancet 1988; 2: 1277–1280.PubMedGoogle Scholar
  159. 146.
    Johnston HH, Herzog JP, Lauler DP. Effect of prostaglandin E1 on renal hemodynamics, sodium and water excretion. Am J Physiol 1967; 213: 939–946.PubMedGoogle Scholar
  160. 147.
    Fülgraff G, Brandenbusch G. Comparison of the effects of prostaglandins A1, E2, and F2a on kidney function in dogs. Pflüger’s Archiv 1974; 349: 9–17.Google Scholar
  161. 148.
    Chang LCT, Splawinski JA, Oates JA, Nies AS. Enhanced renal prostaglandin production in the dog. Effects on renal function; effects on intrarenal hemodynamics. Circ Res 1975; 36: 197–207.Google Scholar
  162. 149.
    Strandhoy JW, Ott E, Schneider EG, Willis LR, Beck NP, Davis BB, Knox FG. Effects of prostaglandins E1 and E2 on renal sodium reabsorption and Starling forces. Am J Physiol 1974; 226: 1015–1021.PubMedGoogle Scholar
  163. 150.
    Paller M. The prostaglandin E1 analog misoprostol reverses acute cyclosporine nephrotoxicity. Transplant Proc 1988; 20(Suppl 3): 634–637.PubMedGoogle Scholar
  164. 151.
    Weir MR, Klassen DK, Hall PS, Schubert C. Misoprostol minimizes indomethacin-induced renal dysfunction in healthy women: a preliminary report. In: Abstract book 22nd Annual Meeting of the American Society of Nephrology. Washington DC; 1989: 309A.Google Scholar
  165. 152.
    Antillon M, Cominelli F, Los S, Somberg K, Moran M, Reynolds TB, Zipser RD. Effect of oral prostaglandin in indomethacin induced renal dysfunction on alcoholic cirrhosis: a double-blind randomized study. Gastroenterology 1988; 94: A522.Google Scholar
  166. 153.
    Boers M, Dijkmans BAC, Breedveld FC, Camps JA, Chang PC, Van Brummelen P, Pauwels EK, Cats A. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac. Brit J Rheumatol 1991; 30: 56–59.Google Scholar
  167. 154.
    Whelton A, Scott H, Stout RL. Effects of misoprostol on nonsteroidal anti-inflammatory drug induced renal insufficiency in patients with stable chronic renal failure: a double-blind, crossover study. Am J Therap 1995; 2(11): 858–863.Google Scholar
  168. 155.
    Gurkowski L, MacDougal M, Weigmann T. Effects of misoprostol on contrast-induced renal dysfunction. Am J Therap 1995; 2(11): 837–842.Google Scholar
  169. 156.
    Russell MW, Miller JD, Taylor DCA, Huse DM: Projected risks and costs of cardiovascular disease due to increased systolic blood pressure associated with use of rofecoxib. Am J Hypert 2001; 14: 195A.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Andrew Whelton
    • 1
  • Til Sturmer
    • 2
  • George A. Porter
    • 3
  1. 1.Universal Clinical Research Center and Johns Hopkins UniversityBaltimoreUSA
  2. 2.German Centre for Research on AgeingHeidelbergGermany
  3. 3.Oregon Health Science UniversityPortlandUSA

Personalised recommendations